With around 30 sites across the UK and Ireland, the MS-STAT2 trial will involve 1,180 people with SPMS – a form of the condition that currently has little effective treatment.
Co-funded by the MS Society, MS-STAT2 is the final stage trial of the drug treatment simvastatin for SPMS. This Phase 3 study will confirm whether simvastatin could become amongst the first drugs to slow or stop disability progression for this form of the condition, offering new hope to thousands.
“Simvastatin is one of the most promising treatment prospects for secondary progressive MS in our lifetime. People with this form of the condition have been waiting decades for a drug that works, which is why there’s such excitement around being able to start the trial,” said Dr Jeremy Chataway (UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery), who is leading the trial.
“While it’s still early days, we believe simvastatin could change lives.”
MS affects over 100,000 people in the UK, and most expect to develop a progressive form of the condition. It causes problems with how people walk, move, see, think, and feel.
Simvastatin is currently widely used to treat high cholesterol, and can be taken daily as an oral tablet. Statins have been shown to have an effect on the nervous system in protecting the nerves, and can also act as an anti-inflammatory treatment.
Positive results from a smaller Phase 2 trial – also led by Dr Chataway and published in The Lancet in 2014 – showed simvastatin could improve levels of disability and slow disease progression. It also reduced the rate of brain atrophy (shrinkage), suggesting the treatment could protect nerves from damage in SPMS.
Nearly 30 sites around the UK and Ireland will be recruiting for the trial until the end of 2019, including London, Glasgow, Belfast, and Dublin, and will take six years to complete.
The multi-million pound trial is being funded by the MS Society in collaboration with the National Institute for Health Research (NIHR), the National MS Society (US), the NHS and UK universities.
Dr Susan Kohlhaas, Director of Research at the MS Society, said: “We are incredibly proud to be funding MS-STAT2, because we know what it could mean for people living with progressive MS. This condition is unpredictable, painful, and often exhausting, but finding an effective therapy means debilitating symptoms aren’t inevitable.
“Today if you’re diagnosed with this form of MS you don’t have any options, but we’re getting closer to changing that, and hopefully delivering the solution everyone has been waiting for.”
People with secondary progressive MS who would like to be considered to participate in MS-STAT2 can register their interest at http://ms-stat2.info.
Links
- Register your interest
- Dr Jeremy Chataway's academic profile
- Chataway et al (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet
Volume 383, Issue 9936, 28 June–4 July 2014, Pages 2213-2221
Image
- Dr Jeremy Chataway (Source: MS Society)